Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.62 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | DDX3X | O00571 | 1/20 | 0.61 |
| ▸ | F2R | P25116 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20332958 | 0.98 | ALDH1A1 (0.68) | NPSR1ALDH1A1HPGDSMN1; SMN2KCNK3 | |
| SCHEMBL4218895 | 0.98 | ALDH1A1 (0.68) | NPSR1ALDH1A1HPGDSMN1; SMN2KCNK3 | |
| SCHEMBL12825257 | 0.97 | NPSR1 (0.65) | NPSR1ALDH1A1HPGDSMN1; SMN2KCNK3 | |
| SCHEMBL4230443 | 0.93 | DDX3X (0.65) | NPSR1ALDH1A1HPGDSMN1; SMN2KCNK3 | |
| SCHEMBL20093477 | 0.87 | GAA (0.57) | NPSR1ALDH1A1HPGDSMN1; SMN2KCNK3 | |
| SCHEMBL2383287 | 0.83 | NPSR1 (0.69) | NPSR1ALDH1A1HPGDSMN1; SMN2KCNK3 | |
| SCHEMBL13716767 | 0.83 | GAA (0.56) | NPSR1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL12825253 | 0.83 | ALDH1A1 (0.54) | NPSR1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL13920562 | 0.82 | NPSR1 (1.00) | NPSR1ALDH1A1HPGDSMN1; SMN2KCNK3 | |
| SCHEMBL4448787 | 0.81 | PTPN1 (0.71) | NPSR1ALDH1A1HPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2377856-A1 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | NPSR1 4621/4885ALDH1A1 1040/4885HPGD 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.